LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Pfizer

Open

SectorHealthcare

23.47 0.56

Overview

Share price change

24h

Current

Min

23.08

Max

23.57

Key metrics

By Trading Economics

Income

2.6B

3B

Sales

-4B

14B

P/E

Sector Avg

17

51.198

EPS

0.92

Dividend yield

7.33

Profit margin

21.633

Employees

81,000

EBITDA

2.5B

5.1B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+18.13% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

7.33%

2.40%

Next Earnings

29 Jul 2025

Next Dividend date

13 Jun 2025

Market Stats

By TradingEconomics

Market Cap

-12B

133B

Previous open

22.91

Previous close

23.47

News Sentiment

By Acuity

36%

64%

119 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pfizer Chart

Past performance is not a reliable indicator of future results.

Related News

20 May 2025, 04:13 UTC

Major Market Movers

Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer

1 May 2025, 18:41 UTC

Major Market Movers

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29 Apr 2025, 11:24 UTC

Earnings

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

27 May 2025, 17:59 UTC

Top News

Kennedy, Skipping Regulatory Steps, Limits Use of Covid-19 Shots -- Barrons.com

20 May 2025, 14:46 UTC

Acquisitions, Mergers, Takeovers

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

15 May 2025, 15:20 UTC

Top News

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

12 May 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 May 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 May 2025, 17:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 May 2025, 09:02 UTC

Hot Stocks

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

7 May 2025, 17:01 UTC

Top News

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 May 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5 May 2025, 15:13 UTC

Market Talk
Earnings

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1 May 2025, 14:07 UTC

Earnings

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 May 2025, 11:58 UTC

Earnings

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 May 2025, 11:06 UTC

Earnings

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 May 2025, 10:48 UTC

Earnings

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29 Apr 2025, 19:47 UTC

Earnings

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 Apr 2025, 18:11 UTC

Earnings

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29 Apr 2025, 15:22 UTC

Earnings

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 Apr 2025, 12:03 UTC

Acquisitions, Mergers, Takeovers

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29 Apr 2025, 11:46 UTC

Earnings

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 Apr 2025, 11:42 UTC

Earnings

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 Apr 2025, 11:12 UTC

Earnings

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29 Apr 2025, 10:52 UTC

Earnings

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29 Apr 2025, 10:51 UTC

Earnings

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29 Apr 2025, 10:50 UTC

Earnings

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29 Apr 2025, 10:47 UTC

Earnings

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29 Apr 2025, 10:47 UTC

Earnings

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29 Apr 2025, 10:46 UTC

Earnings

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

Peer Comparison

Price change

Pfizer Forecast

Price Target

By TipRanks

18.13% upside

12 Months Forecast

Average 27.63 USD  18.13%

High 33 USD

Low 23 USD

Based on 18 Wall Street analysts offering 12 month price targets forPfizer - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

5

Buy

13

Hold

0

Sell

Technical Score

By Trading Central

22.855 / 23.85Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

119 / 380 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.